{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009489","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.170228+00:00","generated_at":"2026-06-17T19:47:08.954272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Therapeutics reports FY 2022 net product sales up 25% to $107.7M; net loss narrows to $182M from $220.7M","bullets":["Annual net product sales $107.7M (+25% YoY); Q4 net product sales $30.0M (+45% YoY).","Net loss for FY 2022: $182.0M ($1.67/share) vs $220.7M ($2.24) in 2021; Q4 net loss $19.9M ($0.17).","ZYNRELEF Q4 net sales $3.9M (+44% QoQ); APONVIE launched March 6, 2023 with CMS pass-through status.","Oncology care franchise net sales $97.5M in 2022 (+17% YoY); FY 2023 guidance $99M-$103M.","Cash and investments $84.9M at Dec 31, 2022, down from $157.6M; operating cash used $146.9M in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009489","json":"https://secwatch.observer/filing/0000950170-23-009489.json","markdown":"https://secwatch.observer/filing/0000950170-23-009489.md","text":"https://secwatch.observer/filing/0000950170-23-009489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/hrtx-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:47:08.954272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a5fcd8a8f194d648f662b0ff2eec0426290c54c","claim":"HERON THERAPEUTICS, INC. /DE/ reported the three and twelve months ended December 31, 2022 results: revenue $30.0 million and $107.7 million, net income $19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share, EPS $0.17 per share and $1.67 per share.","evidence_excerpt":"Net product sales for the three and twelve months ended December 31, 2022 were $30.0 million and $107.7 million, respectively, compared to $20.7 million and $86.3 million, respectively, for the same periods in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2022"},{"label":"Revenue","value":"$30.0 million and $107.7 million"},{"label":"Net income","value":"$19.9 million, or $0.17 per share, and $182.0 million, or $1.67 per share"},{"label":"EPS","value":"$0.17 per share and $1.67 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dd32ecc7544aa29e8f89058135e8049245df27d8","claim":"HERON THERAPEUTICS, INC. /DE/ reported full-year 2023 results: revenue $99 million to $103 million. Guidance initiated.","evidence_excerpt":"Heron currently expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$99 million to $103 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}